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Objective/background: A decision about the need for antimicrobial therapy in a patient with
febrile neutropenia after hematopoietic stem cell transplantation (HSCT) is often complicated
because of the low frequency of culture isolation and reduced clinical manifestation of infec-
tion. Usefulness and choice of sepsis biomarkers to distinguish bloodstream infection (BSI) from
other causes of febrile episode is still argued in HSCT recipients in modern epidemiological sit-
uations characterized by the emergence of highly resistant gram-negative microorganisms. In
this study a comparative analysis of diagnostic values of presepsin, procalcitonin (PCT), and
C-reactive protein (CRP) was performed as sepsis biomarkers in adult patients after HSCT in
a condition of high prevalence of gram-negative pathogens.
Methods: A prospective observational clinical study was performed at the Center of Hematol-
ogy and Bone Marrow Transplantation in Minsk, Republic of Belarus. The biomarkers (presepsin,
PCT, and CRP) were assessed in a 4-hour period after the onset of febrile neutropenia episode in
adult patients after HSCT. Microbiologically-confirmed BSI caused by a gram-negative pathogen
was set as a primary outcome.
Results: Clinical and laboratory data were analyzed in 52 neutropenic patients after HSCT aged
18–79 years. Out of the biomarkers assessed, the best diagnostic value was shown in presepsin
(area under the curve [AUC]: 0.889, 95% confidence interval [CI]: 0.644–0.987, p < .0001) withients in a
10.1016/j.
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Please cite this article in press as: Sto
condition of high prevalence of g75% sensitivity and 100% specificity, then in PCT (AUC: 0.741, 95% CI: 0.573–0.869, p = .0037)
with 62% sensitivity and 88% specificity. The optimal cut-off value for CRP was set as 165 mg/L,
while it had an average diagnostic value (AUC: 0.707, 95% CI: 0.564–0.825, p = .0049) with low
sensitivity (40%) and should not be routinely recommended as a biomarker in adult patients
with suspected BSI after HSCT.
Conclusion: Presepsin may be recommended in adult patients with suspected gram-negative
BSI after HSCT as a possible additional supplementary test with a cut-off value of 218 pg/
mL. PCT is inferior to presepsin in terms of sensitivity and specificity, but still shows a good
quality of diagnostic value with an optimal cut-off value of 1.5 ng/mL. CRP showed an average
diagnostic value with low sensitivity (40%) and should not be routinely recommended as a bio-
marker in adult patients with suspected BSI after HSCT in a condition of high prevalence of
gram-negative pathogens.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Bacterial bloodstream infections (BSI) are still one the lead-
ing causes of infectious complications after hematopoietic
stem cell transplantation (HSCT), occurring in approxi-
mately 5–10% of autologous and 20–30% of allogeneic HSCT
recipients [1]. Despite this, an improved level of supportive
care mortality rate due to BSI remains significant, with it
being 24–40% in allogenic HSCT [2–6]. Traditional diagnosis
of BSI includes results of culturing techniques. Positive
blood culture is known to be the most certain method of
diagnosis, but it has a number of limitations. For instance,
in a large percentage of patients it remains negative despite
the typical clinical presentation of sepsis [7]. The other
issue of standard culturing techniques is that it still takes
significant time for the laboratory to give the results to
the doctor. It is well known that the adequate and on-
time prescribed antimicrobial therapy is key to success in
patients with BSI [8]. But there are a number of cases when
it is not clear whether the febrile episode in a concrete
patient is a symptom of BSI or if the patient has any other
cause (e.g., viral or fungal infection, reaction to
chemotherapy infusion, or reactivation of hematologic dis-
ease). In patients receiving HSCT the consequences of BSI
may be dramatic, taking into account the level of immuno-
suppression caused by high-dose chemotherapy and total
body irradiation. The other issue, which may affect the
early diagnosis of BSI in HSCT patients, is the possibility of
having a potentially fatal BSI with mild clinical symptoms
of infection in such patients; though, the clinical signifi-
cance of sepsis biomarkers increases in HSCT recipients.
Among the widely used biomarkers which have been
studied in neutropenic patients are procalcitonin (PCT), C-
reactive protein (CRP), and interleukin-6 [9–11]. Despite
this fact, the use of biomarkers in neutropenic patients
remains a controversial question. For instance, the guideli-
nes of the Infectious Diseases Society of America does not
include the use of biomarkers in their recommendations
[12]. However, the existing studies are based on small sam-
ples of patients receiving HSCT in a total group of neu-
tropenic patients, so there is not enough data to be sure
about the diagnostic and clinical significance of those
biomarkers in HSCT recipients [13,14]. Previously it wasma I et al., Diagnostic value of se
ram-negative pathogens ..., Hemshown that biomarkers are not equally effective in special
groups of patients; however, important differences in diag-
nostic characteristics of presepsin were shown in patients
with advanced forms of acute kidney injury and in patients
on hemodialysis, which served as a need for different cut-
off values in such patients [15,16]. Furthermore, there is
no compelling information concerning the usefulness of pre-
sepsin in adult patients after HSCT, and there is a practical
need for results of a comparative analysis of diagnostic
parameters for PCT, CRP, and presepsin in HSCT recipients
[17,18]. The continuing emergence of gram-negative patho-
gens as a cause of BSI affects transplant centers worldwide,
so the use of biomarkers in patients after HSCT should be
reevaluated according to this recent shift from gram-
positive microorganisms [3,19,20]. Therefore, it is impor-
tant to assess and compare the diagnostic value of pre-
sepsin, PCT, and CRP as early biomarkers of a gram-
negative bacterial BSI in HSCT recipients.
The main objective of the study was to identify the diag-
nostic value of presepsin, PCT, and CRP and perform a com-
parative analysis of those biomarkers in a group of HSCT
recipients with gram-negative bacterial BSI.
Methods
Study setting and design
The Republican Center for Hematology and Bone Marrow
Transplantation is located on the base of the City Clinical
Hospital No. 9 in Minsk, Belarus. The center has more than
150 beds including a Department of Bone Marrow Transplan-
tation and Intensive Care Unit for patients with various
hematological diseases, with patients preparing and under-
going HSCT. It also includes a microbiology laboratory, lab-
oratory of bone marrow separation and freezing, laboratory
of cellular biotechnology, HLA-typing laboratory, and clini-
cal diagnostics laboratory. The study was approved by the
Institutional Research Ethics Committee of the hospital,
and informed consent was taken from the included patients.
Data relating to age, sex, date, and type of transplanta-
tion, conditioning chemotherapy regimen, microorganisms
isolated from blood, and antibacterial therapy were
prospectively collected in hematopoietic stem cell recipi-psis biomarkers in hematopoietic stem cell transplant recipients in a
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Sepsis biomarkers in HSCT recipients 3ents in this observational clinical study. There were 52 adult
patients who had undergone autologous or allogeneic HSCT
with neutropenia—all of them were inpatients. The study was
performed between January 2013 and October 2015.
The inclusion criteria of the study included adult patients
with febrile neutropenia during 30 days (pre-engraftment
period) after autologous or allogenic HSCT. Febrile neu-
tropenia was assessed by definition of Freifeld et al. [12]
as a single oral temperature measurement of >38.3 C or a
temperature of >38.0 C sustained over a 1-hour period with
an absolute neutrophil count (ANC) in peripheral blood of
6500 cells/mm3 or an ANC that is expected to decrease to
6500 cells/mm3 during the next 48 hours. Among the exclu-
sion criteria were diabetes mellitus, acute kidney injury
(clinically and/or laboratory confirmed), and acute heart
failure. Patients, who had received antithymocytic
immunoglobulin during 7 days before the onset of the feb-
rile episode were excluded from the study. BSI was defined
as having a microbiologically-proven growth from a blood
culture of a patient with febrile neutropenia in a period of
30 days after HSCT, which was taken as an endpoint in the
analysis. In a case of fatal outcome, blood samples were still
included in the analysis.
Laboratory methods
Blood samples for presepsin, PCT, and CRP were obtained in
all of the included patients during the period up to 4 hours
after the onset of febrile neutropenia. Blood samples (for
microbiological analysis and biomarker detection) were
taken before the initiation of empiric antibacterial therapy
in all patients included in this study. CRP was measured in
blood by automatic biochemical analyzer Architect c8000
(Abbott Laboratories, Abbott Park, Illinois, USA) with the
reagents from Dialab (Vienna, Austria). PCT in blood was
measured by automatic analisator miniVIDAS/Blue with
the reagents VIDAS BRAHMS PCT from BioMerieux (Marcy
l’Etoile, France). Presepsin was measured in EDTA – blood
taking into consideration the hematocrit level by automatic
analisator PATHFAST and PATHFAST presepsin reagent from
company Mitsubishi Chemical Medience Corporation (Tokyo,
Japan). The cut-offs for the biomarker levels were
determined prior to initiating the test. Isolation of patho-
gens was performed by standard means with BacT/ALERT
Standard Aerobic/Anaerobic bottles and BacT/ALERT
three-dimensional automated microbial detection system,
Biomerieux (Marcy l’Etoile, France). Identification and
antibiotic resistance was studied with VITEK 2 system by
Biomerieux (Marcy l’Etoile, France), E-tests, and disc-
diffusion methods.
Transplantation procedure and management of
infections
Transplantation was performed according to institutional
protocols. Briefly, the most frequent myeloablative condi-
tioning regimens were busulfan and cyclophosphamide,
cyclophosphamide, and total body irradiation (cyclophos-
phamide + total body irradiation). Nonmyeloablative and
reduced intensity conditioning mainly included fludarabine
with melphalan or treosulfan and BEAM regimen (car-Please cite this article in press as: Stoma I et al., Diagnostic value of sep
condition of high prevalence of gram-negative pathogens ..., Hemmustine, etoposide, cytarabine, melphalan). Graft versus
host disease prophylaxis regimens included cyclosporine,
methotrexate, and tacrolimus. Antithymocyte globulin was
administered in cases of unrelated donors. Standard
antibacterial prophylaxis in the department was based on
fluoroquinolones (mainly ciprofloxacin 0.5 g orally twice a
day) starting from the initiation of conditioning regimen
until the time when level of neutrophils in peripheral blood
exceeded 500 cells/mm3. No routine antibacterial prophy-
laxis against Streptococcus pneumoniae was administered.
Antifungal prophylaxis with fluconazole was prescribed to
patients undergoing autologous HSCT and micafungin was
used as antifungal prophylaxis in patients undergoing allo-
geneic HSCT. Prophylaxis against Pneumocystis jirovecii
with trimethoprim–sulfamethoxazole was administered to
all patients until immunologic recovery after HSCT. Prophy-
laxis of infections caused by the herpes viruses was per-
formed by acyclovir. Real-time quantitative polymerase
chain reaction was used for monitoring cytomegalovirus
(CMV) DNA levels in HSCT patients weekly during the pre-
engraftment period, with ganciclovir used as first line pre-
emptive therapy in case of possible active CMV infection
and exclusion of such patients from the conducted study.
During the period of severe neutropenia (ANC <100 cells/
mm3) all patients were isolated in single rooms with positive
pressure, laminar air flow and high-efficiency particulate air
filtration. After the ANC exceeded 100 cells/mm3 some of
the clinically stable patients were moved to the intensive
care department, with two patients remaining in a room
and positive air pressure.
The institution’s standard protocols of initial empirical
antibiotic therapy for febrile neutropenia included cepha-
losporins (cefepime or cefoperazone/sulbactam) or car-
bapenems (imipenem/cilastatin or meropenem) depending
on the risk group of the patient with an addition of van-
comycin in case of possible infection caused by gram-
positive pathogens [19].
Statistical analysis
Data processing and analysis were performed using MedCalc
Statistical Software version 14.10.2 (MedCalc Software
bvba, Ostend, Belgium). Receiver operating characteristic
(ROC) analysis was performed with the DeLong et al. [21]
method. Probabilities <.05 were considered significant.
Classification of quality levels of diagnostic models is shown
in Table 1.
Results
In total, there were 52 patients with febrile neutropenia
after HSCT included. The age of patients was 18–79 years
with a median age of 41 years (25–75 years, percentiles:
28–51 years). Among them were 28 (53.8%) women and 24
(46.2%) men. Among the primary diagnoses were acute mye-
loid leukemia, Hodgkin’s lymphoma, multiple myeloma, and
nonHodgkin lymphomas. Among the patients, eight received
related allogeneic HSCT, four patients received unrelated
allogeneic HSCT, and 40 patients received autologous HSCT.
Microbiologically gram-negative BSI was proven in 30
patients, and in 22 patients bacterial etiology of the febrilesis biomarkers in hematopoietic stem cell transplant recipients in a
atol Oncol Stem Cell Ther (2016), http://dx.doi.org/10.1016/j.
Table 1 Levels of quality of diagnostic models in receiver
operating characteristic (ROC) analysis






Fig. 1 ROC curve for C-reactive protein.
4 I. Stoma et al.episode was excluded by way of multiple blood (or sputum)
sample microbiological analysis and additional clinical
investigation (chest X-ray, urine analysis). After exclusion
of bacterial BSI, the causes of febrile neutropenia in the
other 22 patients were discussed individually. Most of them
were noninfectious febrile reactions: only three of them had
CMV reactivation proven by means of quantitative poly-
merase chain reaction and one patient had candidemia
caused by Candida albicans. Table 2 shows the baseline
demographic and clinical characteristics of the patients
included in the study.
CRP showed a poor level of sensitivity (40%), while it had
91% specificity in the analysis. The positive likelihood ratio
of CRP was 4.40 (95% confidence interval [CI]: 1.1–17.7),
while the negative likelihood ratio was 0.66 (95% CI: 0.5–
0.9). The specificity of CRP was 100% at the level of
225.7 mg/L, and the optimal cut-off value in such patients
was 165 mg/L. Area under the ROC curve (AUC) for CRP
was 0.707 (95% CI: 0.564–0.825, p = .0049), which can be
used to assess the quality of the model as an average.
ROC-curve for CRP as a biomarker of gram-negative BSI is
shown in Fig. 1.
The optimal cut-off value for PCT as a biomarker of
gram-negative BSI in patients after HSCT was shown at 1.5
ng/mL, while the sensitivity was 62% and specificity 88%.Table 2 Demographical and clinical baseline characteris-
tics of patients with febrile neutropenia in the pre-engraft-
ment period after hematopoietic stem cell transplantation
(HSCT)
Baseline characteristics Absolute No.
(n = 52, %)
Age, y (median, interquartile range) 41 (28–51)






Nonmyeloablative/reduced intensity 43 (82.7)
Primary diagnosis:
Acute myeloid leukemia 12 (23.1)
Hodgkin’s lymphoma 6 (11.5)
Multiple myeloma 9 (17.3)
NonHodgkin’s lymphoma 25 (48.1)
Please cite this article in press as: Stoma I et al., Diagnostic value of se
condition of high prevalence of gram-negative pathogens ..., HemThe specificity was shown to be 100%, while PCT was
26.7 ng/mL. The AUC for PCT was 0.741 (95% CI:
0.573–0.869, p = .0037), which can be used to assess the
quality of this model as an average. The positive likelihood
ratio for PCT was 5.26 (95% CI: 1.4–20.2) with a negative
value of 0.43 (95% CI: 0.2–0.8).
The optimal cut-off value for presepsin as a biomarker of
gram-negative BSI was shown to be at 218 pg/mL, while its
sensitivity was 75% and specificity was 100%. The negative
likelihood ratio for presepsin was 0.25 (95% CI: 0.08–
0.80), while the positive likelihood ratio was not calculated
due to the 100% specificity parameter. The AUC for pre-
sepsin was shown to be 0.889 (95% CI: 0.644–0.987,
p < .0001), which can be used to assess the quality of this
model as good. Results of the comparative analysis of diag-
nostic parameters of presepsin, CRP, and PCT as biomarkers
of gram-negative BSI in adult patients after HSCT are pre-
sented in Table 3. The spectrum of pathogens which caused
gram-negative BSI in patients after HSCT is shown in
Table 4.
Therefore, among the causes of gram-negative BSI in
adult patients after HSCT in the conducted study gram-
negative nonfermenting microorganisms had 33.33%, and
the members of the Enterobacteriaceae family had 66.67%
in a total etiological spectrum.
Discussion
PCT is used as a biomarker of systemic bacterial infections
in adults and children [22,23]. There have been described
nonspecific elevations of PCT in certain groups of patients,
for example, elevation was described in neonates during the
1st 18–30 hours up to 20 ng/mL with a decrease of biomar-
ker to 1.5 ng/mL by 72 hours [24]. Nonspecific elevations of
PCT were also described in patients with severe trauma,
burns, massive surgical interventions, even with chronic kid-psis biomarkers in hematopoietic stem cell transplant recipients in a
atol Oncol Stem Cell Ther (2016), http://dx.doi.org/10.1016/j.
Table 3 Diagnostic parameters of presepsin, c-reactive protein, and procalcitonin as biomarkers of gram-negative bloodstream
infection in adult patients after hematopoietic stem cell transplantation
Diagnostic parameter Biomarker
C-reactive protein Procalcitonin Presepsin
Cut-off value 165 mg/L 1.5 ng/mL 218 pg/mL
Sensitivity (%) 40 62 75
Specificity (%) 91 88 100

















Stand. error 0.0735 0.0831 0.085
p .0049 .0037 <0.0001
Quality of model Average Average Good
Note: CI = confidence interval; ROC = receiver operating characteristic; Stand. = standard.
Table 4 Causes of gram-negative bloodstream infection





Klebsiella pneumoniae 12 40
Escherichia coli 8 26.67
Acinetobacter baumannii 6 20
Pseudomonas aeruginosa 4 13.33
Sepsis biomarkers in HSCT recipients 5ney failure [25]. There are data published concerning the
use of PCT in patients after solid organ transplantation,
for example, researchers have shown that the use of PCT
as a biomarker of bacterial infection is possible in patients
after liver transplantation and heart transplantation
[26,27]. Nonspecific elevation of PCT and CRP were demon-
strated in patients receiving antithymocytic immunoglobu-
lin, T-cell therapy, certain chemotherapy regimens
[28,29]. C-reactive protein is a widely used inflammatory
marker—one of the so-called acute phase proteins. It was
shown to increase at various conditions: infections, trauma,
autoimmune diseases, acute cardiologic diseases, and graft
versus host disease [18]. Presepsin is a novel sepsis biomark-
ers recently being implemented in clinical practice. Sho-
zushima et al. [30] have shown that presepsin is an
effective diagnostic marker in case of a BSI, but large
enough samples of patients after HSCT have not been eval-
uated yet as a separate group in various studies on presepsin
use. In other populations it was shown that the level of pre-
sepsin shortly decreases after initiating antibacterial ther-
apy, which makes it important to study this aspect in
HSCT recipient populations [31]. All of the patients included
in the study had their blood samples taken up to 4 hours
after the onset of the febrile episode, so the results may
be used to assess the early diagnostic characteristics of
biomarkers in HSCT recipients. As it was shown previously,
the time to prescribing antibiotics is extremely important:Please cite this article in press as: Stoma I et al., Diagnostic value of sep
condition of high prevalence of gram-negative pathogens ..., Hemin septic patients antibiotics should be started within 1 hour
from the diagnosis, and if the antibacterial therapy is
delayed in a patient with septic shock, mortality may
increase by 7.6% per hour [32].
The results of the comparative analysis of diagnostic
parameters of sepsis biomarkers in adult patients with
gram-negative BSI after HSCT showed that the best level
of quality in this condition demonstrates more of a diagnos-
tic model with presepsin (AUC: 0.889, 95% CI: 0.644–0.987,
p < .0001) than PCT (AUC: 0.741, 95% CI: 0.573–0.869,
p = .0037). CRP does not have an adequate enough sensitiv-
ity (40%) to be widely recommended as a sepsis biomarker in
adult patients with gram-negative BSI after HSCT and its
cut-off value in this condition should be at concentration
of 165 mg/L. It is important to underline that these data
concern the levels of biomarkers only at the first 24 hours
after the onset of febrile neutropenia, as a most important
period, because the outcome of BSI in neutropenic patient
significantly depends on adequate empiric antibacterial
therapy prescribed in the first 24 hours of possible infectious
complication. Results of the microbiological part of the
study confirm that gram-negative BSI in patients after HSCT
are mostly caused by members of the Enterobacteriaceae
family (66.67%), with an important influence from nonfer-
menters (33.33%). Results of recent meta-analysis including
2159 sepsis cases, conducted by Wu et al. [31] showed a
pooled sensitivity of presepsin for sepsis to be 78% (95%
CI: 76–80%), while pooled specificity was 83 (95% CI: 80–
85%), pooled positive likelihood ratio was 4.63 (95% CI:
3.27–6.55), and pooled negative likelihood ratio was 0.22
(95% CI: 0.16–0.30); the AUC of the summary ROC curve
was 0.89 (95% CI: 0.84–0.94), which is close to the data
achieved in our study. Zhang et al. [33] have also conducted
a meta-analysis, including 11 published studies, with the
overall diagnostic sensitivity of presepsin for sepsis being
83% (95% CI: 77–88%), specificity of 78% (95% CI: 72–83%),
and the AUC of 88% (95% CI: 84–90%). Still, it is important
to state that the sensitivity of presepsin in HSCT in our study
was slightly lower than in the above named meta-analyses
(75% vs. 78%; 75% vs. 83%).sis biomarkers in hematopoietic stem cell transplant recipients in a
atol Oncol Stem Cell Ther (2016), http://dx.doi.org/10.1016/j.
6 I. Stoma et al.As limitations of the study we may mention the relatively
small sample, which is too small to build a firm conclusion
from it, but concerning the cost of every HSCT procedure
and high risk of fatal outcome in case of BSI, even such num-
bers of observations may be important. The other limitation
was that the measurement of biomarkers was only during
the first 4 hours after onset of febrile episode, because mul-
tiple measurements were not possible to perform in all of
the patients. Finally, this study was conducted in one clini-
cal center, but it is important to mention that this center
performs HSCT for patients from all parts of our country.
The end-point in the conducted study also has some impor-
tant limitations, because it is based only on BSIs and con-
cerns only gram-negative pathogens, while in some regions
of the world gram-positive infections still remain as leading
causes of sepsis in immunocompromised hosts [1] and we
could still have been missing active infections without
bacteremia (pneumonia or urinary tract infections in neu-
tropenic patients may not have the clear manifestations).
Although presepsin is the receptor of lipopolysaccharide-
lipopolysaccharide binding protein complexes—an important
component of gram-negative bacterial cell wall—previous
studies showed no disparity of serum presepsin concentra-
tion between infections caused by gram-negative and
gram-positive pathogens [31,34]. Therefore, research ques-
tions remain important to study in future works with HSCT
recipients.
Conclusions
In comparison with the rest of the biomarkers, presepsin
determined in the first 24 hours after the onset of the feb-
rile episode has shown a relatively higher diagnostic value as
a marker of BSI caused by gram-negative pathogens in adult
patients after HSCT with an optimal cut-off value of 218 pg/
mL. PCT was also effective in diagnosing BSI with a cut-off
value of 1.5 ng/mL, but its relatively low sensitivity (62%)
may become a cause of clinically dangerous false-negative
results of test. The use of CRP as a biomarker of gram-
negative BSI should not be routinely recommended in adult
patients after HSCT because of average diagnostic quality
and low sensitivity (40%); still, in such cases an optimal
cut-off value for CRP should be at 165 mg/L.
Common clinical practice in the area of febrile neutrope-
nia management is based on an immediate search for infec-
tious foci and a haste to initiate antibiotic therapy after
taking samples for cultures. Later, the decision to modify
or stop antibacterial therapy depends on the workup, which
often takes a lot of time. This means that the patient would
be committed to broad-spectrum antibiotics for some time
before the culture results reveal a pathogen—a practice that
has led to the worldwide antimicrobial resistance catastro-
phe. Furthermore, cultures may turn out to be negative in
40% of patients with sepsis [35]. Therefore, there is a need
for a rapid test that could help to rule out an infectious
cause quickly. Hence, a biomarker would be most useful
as a screening test (i.e., a negative value confirms the
absence of infection). A good screening test is characterized
by a great sensitivity. However, the sensitivities found in
this study are still not high enough to recommend them
among the tests that should be taken in face of febrile neu-Please cite this article in press as: Stoma I et al., Diagnostic value of se
condition of high prevalence of gram-negative pathogens ..., Hemtropenia in HSCT patients (presepsin sensitivity was 75%).
Therefore, presepsin may only be recommended as a possi-
ble additional supplementary test in a febrile neutropenic
patient after HSCT to rule out sepsis, caused by gram-
negative pathogen, when the pretest probability of sepsis
is already borderline, and clinicians are hesitant about
keeping the patient off antibiotics.
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